Labcorp director receives 897 shares from RSU vesting

Labcorp Holdings Inc. director Jeffrey A. Davis acquired common shares through equity compensation.

Rhea-AI Filing Summary

Labcorp Holdings Inc. director Jeffrey A. Davis acquired common shares through equity compensation. On February 11, 2026, 897 Restricted Stock Units were exercised/converted at $0 into 897 shares of Labcorp common stock. After this transaction, Davis directly held 5,460 common shares and 773 Restricted Stock Units.

Insider Trade Summary

897 shares exercised/converted

Exercise 2 txns

Insider Davis Jeffrey A.

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Unit	897	$0.00	$0.00
Exercise	Common Stock	897	$0.00	$0.00

Holdings After Transaction: Restricted Stock Unit — 773 contracts (Direct); Common Stock — 5,460 shares (Direct)

Footnotes (3)

1. F1. Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.
2. F2. The Restricted Stock Units vested fully on February 11, 2026.
3. F3. This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Labcorp (LH) director Jeffrey A. Davis report?

Jeffrey A. Davis reported an equity compensation-related transaction. On February 11, 2026, 897 Restricted Stock Units were exercised or converted at $0 into 897 shares of Labcorp common stock, increasing his directly held common shares to 5,460.

Was the Labcorp (LH) insider Form 4 a stock purchase or RSU vesting?

The Form 4 reflects RSU vesting and conversion, not an open-market stock purchase. 897 Restricted Stock Units vested and were exercised or converted at $0 into 897 Labcorp common shares as part of Davis’s equity compensation program.

How many Labcorp (LH) shares does Jeffrey A. Davis own after this Form 4?

Following the reported transaction, Jeffrey A. Davis directly owns 5,460 shares of Labcorp common stock. He also holds 773 Restricted Stock Units, which represent rights to receive additional Labcorp shares upon future vesting or settlement conditions.

What do the Restricted Stock Units in the Labcorp (LH) Form 4 represent?

Each Labcorp Restricted Stock Unit represents a contingent right to receive one share of common stock. In this filing, 897 Restricted Stock Units vested fully on February 11, 2026 and were converted into an equal number of Labcorp common shares at no exercise price.

Did Labcorp (LH) director Jeffrey A. Davis sell any shares in this Form 4?

No share sales are reported in this Form 4. The transactions are coded "M" for exercise or conversion of derivative securities, showing RSUs vesting into 897 Labcorp common shares, with no reported open-market or disposition transactions.

How many Restricted Stock Units does the Labcorp (LH) director still hold?

After the RSU vesting and conversion on February 11, 2026, Jeffrey A. Davis holds 773 Restricted Stock Units. This figure reflects the aggregate number of Labcorp Restricted Stock Units that remain credited to him after the reported transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/13/2026 - 12:48 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Davis Jeffrey A.

(Last) (First) (Middle)

531 SOUTH SPRING STREET

(Street)

BURLINGTON NC 27215

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LABCORP HOLDINGS INC. [ LH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/11/2026		M		897	A	(1)	5,460	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	02/11/2026		M			897	(2)	(2)	Common Stock	897	$0	773(3)	D

Explanation of Responses:

1. Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.

2. The Restricted Stock Units vested fully on February 11, 2026.

3. This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

	/s/ Kathryn W. Kyle, Attorney-in-Fact for Jeffrey A. Davis	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.